A Randomized Phase II Study of Androgen Deprivation Therapy with or without Palbociclib in RB-positive Metastatic Hormone-Sensitive Prostate Cancer.
Phillip L PalmbosStephanie Daignault-NewtonScott A TomlinsArchana M AgarwalPrzemyslaw TwardowskiAlicia K MorgansWm Kevin KellyVivek K AroraEmmanuel S AntonarakisJaved SiddiquiJon A JacobsonMatthew S DavenportDan R RobinsonArul M ChinnaiyanKaren E KnudsenMaha HussainPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2021)
Palbociclib did not impact outcome in RB-intact mHSPC. Pretreatment CTC, TP53 and PIK3 pathway mutations, and 8q gain were associated with poor outcome.